Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy.
Kate GregoryDylan HansenRoss PenglaseDiane ApostolopoulosGene-Siew NgianWendy StevensKathleen MorrisroeNava FerdowsiLaura J RossJennifer WalkerHelen CooleyPeter YoussefKathleen TymmsLauren HostSusanna M ProudmanJohn MooreMandana NikpourJoanne SahharPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2024)
ASCS patients meeting ASTIS and/or SCOT inclusion criteria who were not treated with ASCT have similar EFS at 4 years as patients receiving ASCT and better EFS than those receiving cyclophosphamide in the ASTIS and SCOT trials. This may reflect confounders unable to be controlled for, including survivor bias, but may also reflect improved standard of care for dcSSc over time.
Keyphrases
- systemic sclerosis
- stem cell transplantation
- high dose
- newly diagnosed
- interstitial lung disease
- end stage renal disease
- ejection fraction
- healthcare
- chronic kidney disease
- palliative care
- peritoneal dialysis
- prognostic factors
- bone marrow
- adipose tissue
- type diabetes
- stem cells
- mesenchymal stem cells
- pain management
- patient reported outcomes
- idiopathic pulmonary fibrosis
- high grade